{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:41:54Z","timestamp":1784662914181,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier","isbn-type":[{"value":"9780128022566","type":"print"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/bs.acc.2015.05.001","type":"book-chapter","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T13:31:48Z","timestamp":1435066308000},"page":"1-23","source":"Crossref","is-referenced-by-count":93,"title":["Biomarkers in Breast Cancer"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2015.05.001_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000338393","article-title":"Tumor markers in clinical practice: a review focusing on common solid cancers","volume":"22","author":"Duffy","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/bs.acc.2015.05.001_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-med-070912-143853","article-title":"Molecular testing in breast cancer","volume":"65","author":"Paoletti","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0020","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0030","first-page":"309","article-title":"Identifying and testing for hereditary susceptibility to cancer","volume":"54","author":"Sifri","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.acc.2015.05.001_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrc1301","article-title":"Genetic testing for cancer susceptibility","volume":"4","author":"Lerman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0040","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/bs.acc.2015.05.001_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/10408363.2013.865700","article-title":"Precision treatment for cancer: role of prognostic and predictive markers","volume":"51","author":"Duffy","year":"2014","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2015.05.001_bb0050","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers","volume":"88","author":"Hayes","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13058-014-0428-4","article-title":"uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies","volume":"16","author":"Duffy","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0060","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jnci\/93.12.913","article-title":"Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1","volume":"93","author":"Janicke","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","article-title":"Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients","volume":"94","author":"Look","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0070","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2013.01.007","article-title":"Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients","volume":"49","author":"Harbeck","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0075","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0080","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1373\/clinchem.2007.094144","article-title":"National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2015.05.001_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer\u2014European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0090","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Breast Cancer. Version 2. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#breast (accessed 1 April 2015)."},{"key":"10.1016\/bs.acc.2015.05.001_bb0095","first-page":"2817","article-title":"A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer","volume":"347","author":"Paik","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0100","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0105","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, ER-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0115","unstructured":"http:\/\/www.cancer.gov\/clinicaltrials\/noteworthy-trials\/tailorx."},{"key":"10.1016\/bs.acc.2015.05.001_bb0120","unstructured":"http:\/\/swog.org\/Visitors\/S1007\/patients.asp."},{"key":"10.1016\/bs.acc.2015.05.001_bb0125","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2015.05.001_bb0130","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0135","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(07)70346-7","article-title":"Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)","volume":"8","author":"Bueno-de-Mesquita","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","article-title":"The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer","volume":"120","author":"Knauer","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/bs.acc.2015.05.001_bb0145","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ijc.28082","article-title":"A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study","volume":"133","author":"Drukker","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0150","doi-asserted-by":"crossref","first-page":"8461","DOI":"10.1007\/s13277-014-2366-2","article-title":"Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use","volume":"35","author":"Zanotti","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2014-0124","article-title":"Genome-based risk prediction for early stage breast cancer","volume":"19","author":"Adaniel","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/bs.acc.2015.05.001_bb0160","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","volume":"33","author":"Sestak","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/bs.acc.2015.05.001_bb0170","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2-breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djt146","article-title":"Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker","volume":"105","author":"Sgroi","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"38","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.05.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/bcr3636","article-title":"Status of adjuvant endocrine therapy for breast cancer","volume":"16","author":"Schiavon","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0195","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2015.05.001_bb0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13277-010-0025-9","article-title":"Evaluation of tumor markers (HER-2\/neu oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer: prognostic value","volume":"31","author":"Molina","year":"2010","journal-title":"Tumor Biol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10408360600739218","article-title":"Estrogen receptors: role in breast cancer","volume":"43","author":"Duffy","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2015.05.001_bb0210","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/ERC-12-0389","article-title":"A bi-faceted role of estrogen receptor \u03b2 in breast cancer","volume":"20","author":"Leygue","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2015.05.001_bb0220","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1530\/ERC-10-0162","article-title":"A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer","volume":"18","author":"Petit","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0225","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0230","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0235","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","article-title":"Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27\u2014a randomized controlled phase III trial","volume":"31","author":"Goss","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0240","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","article-title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0245","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0250","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0255","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1309\/AJCP34CYSATWFDPQ","article-title":"Low ER+ breast cancer: is this a distinct group?","volume":"141","author":"Gloyeske","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0265","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","article-title":"Which threshold for ER positivity? A retrospective study based on 9639 patients","volume":"25","author":"Yi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0270","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","article-title":"Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance","volume":"97","author":"Arpino","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0275","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","article-title":"Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases","volume":"21","author":"Bardou","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0280","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1158\/1078-0432.CCR-06-0248","article-title":"High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients","volume":"12","author":"Stendahl","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0285","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdl016","article-title":"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status","volume":"17","author":"Dowsett","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-009-0318-0","article-title":"Progesterone receptor is a significant factor associated with clinical outcome and effect of adjuvant tamoxifen therapy in breast cancer patients","volume":"119","author":"Liu","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/bs.acc.2015.05.001_bb0295","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2015.05.001_bb0300","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0305","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Giordano","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0310","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guidelines update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0315","doi-asserted-by":"crossref","first-page":"dju034","DOI":"10.1093\/jnci\/dju034","article-title":"Promoting quality and evidence-based care in early-stage breast cancer follow-up","volume":"106","author":"Henry","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(98)00297-4","article-title":"The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers","volume":"35","author":"Robertson","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0325","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02968047","article-title":"Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study","volume":"11","author":"Kurebayashi","year":"2004","journal-title":"Breast Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0330","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.2015.8","article-title":"Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase","volume":"112","author":"Di Gioia","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2015.05.001_bb0335","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/cncr.22292","article-title":"The role of FDG-PET\/CT in suspected recurrence of breast cancer","volume":"107","author":"Radan","year":"2006","journal-title":"Cancer"},{"issue":"Suppl. 6","key":"10.1016\/bs.acc.2015.05.001_bb0340","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/ctrv.1999.0151","article-title":"Tumour marker measurements in the diagnosis and monitoring of breast cancer","volume":"26","author":"Cheung","year":"2000","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/bs.acc.2015.05.001_bb0350","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0355","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdu018","article-title":"Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research","volume":"25","author":"Grover","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0360","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-13-2030","article-title":"Real-time liquid biopsy in cancer patients: fact of fiction","volume":"73","author":"Pantel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0365","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2015.05.001_bb0370","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0375","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0380","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2015.05.001_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2015.05.001_bb0390","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2015.05.001_bb0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/511524a","article-title":"Cancer biomarkers: written in blood","volume":"511","author":"Yong","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2015.05.001_bb0400","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/bs.acc.2015.05.001_bb0405","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3446","article-title":"Circulating nucleic acids as biomarkers in breast cancer","volume":"15","author":"Schwarzenbach","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/bs.acc.2015.05.001_bb0410","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2015.05.001_bb0415","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1373\/clinchem.2014.221341","article-title":"Circulating microRNA biomarker studies: pitfalls and potential solutions","volume":"61","author":"Witwer","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2015.05.001_bb0420","first-page":"311","article-title":"MicroRNAome genome: a treasure for cancer diagnosis and therapy","volume":"64","author":"Berindan-Neagoe","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.acc.2015.05.001_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057841","article-title":"Dampening enthusiasm for circulating microRNA in breast cancer","volume":"8","author":"Leidner","year":"2013","journal-title":"PLoS One"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242315000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242315000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:33:18Z","timestamp":1758742398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242315000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9780128022566"],"references-count":85,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2015.05.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}